Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Assisting biopharmaceutical drug discovery and development, particularly with regard to monoclonal antibodies, Sphere Fluidics has developed an integrated platform capable of processing, assaying, sorting and dispensing single cells.
The London-based translational research company is pioneering the development of innovative imaging biomarkers to enhance efficiency and reduce risk in the development of drugs for therapeutic areas such as inflammation and respiratory disease.
Celonic is a private Swiss biotech company specializing in the production of recombinant proteins in mammalian cell systems for use in any stage of drug development.
Imanova helps companies accelerate their drug development programs by providing imaging tools for de-risking lead compounds early in humans, thereby reducing late-stage attrition.
Celonic is a private Swiss biotech company specializing in the production of recombinant proteins in mammalian cell systems for use in any stage of drug development
Early-stage drug screening. Brainwave-Discovery provides medium throughput drug screening in early stage drug discovery for Alzheimer’s, Parkinson’s and Huntington’s diseases.
A commercial environment reinvigorated by improved fundamentals—increased regulatory flexibility and the emergence of exciting new scientific opportunities and innovative business models—has set the stage for a resurgence in the antibiotics space that has already led to an uptick in early-stage venture investment and strategic partnerships.
Helperby’s antibiotic-resistance breakers are a powerful tool serving to prolong and boost antibiotic efficacy and should help counter the growing global crisis of antibiotic resistance.
F-star is developing a promising pipeline of immuno-oncology therapies with its innovative bispecific antibody technology, which is ideally suited to uncover novel combinatorial biology.
With OC459, a first-in-class, oral, once-a-day small molecule for atopic dermatitis, Atopix has a potential winner for this and other type 2 helper T cell–mediated disorders such as severe asthma and related allergic conditions.
LEO Pharma is focusing on improving outcomes for those living with skin diseases and is seeking new strategic partnerships to change the treatment paradigm in dermatology.
The dermatology space is emerging from an active period of diversification and consolidation that has opened up new partnering opportunities. Besides the cosmetic market, the medical segment has also entered a growth phase propelled by three indications: melanoma, psoriasis and systemic lupus erythematosus.
Building on the huge success of monoclonal antibody therapeutics, the next generation of antibody-based products such as bispecifics and antibody-drug conjugates is now opening up new opportunities.
BTG combines medicines, device technology and new techniques to deliver more targeted treatments, and is leading the way in bringing these innovative interventional medicine therapies to market.
